Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Cancer-Associated AA Amyloidosis Presenting as Crescentic Glomerulonephritis.

Zuckerman JE, Peng F, Karl BE, Schulze CE, Sisk A.

Kidney Int Rep. 2019 Mar 4;4(6):882-887. doi: 10.1016/j.ekir.2019.02.017. eCollection 2019 Jun. No abstract available.

2.

Virtual histological staining of unlabelled tissue-autofluorescence images via deep learning.

Rivenson Y, Wang H, Wei Z, de Haan K, Zhang Y, Wu Y, Günaydın H, Zuckerman JE, Chong T, Sisk AE, Westbrook LM, Wallace WD, Ozcan A.

Nat Biomed Eng. 2019 Jun;3(6):466-477. doi: 10.1038/s41551-019-0362-y. Epub 2019 Mar 4.

PMID:
31142829
3.

Acute Kidney Injury in a Patient Following Kidney Transplantation.

Qaqish SS, Zuckerman JE, Danovitch GM, Lum EL.

Am J Kidney Dis. 2019 Jan;73(1):A15-A19. doi: 10.1053/j.ajkd.2018.09.007. No abstract available.

PMID:
30579385
4.

Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall.

Zuckerman JE, Moatamed NA.

Rare Tumors. 2017 Oct 3;9(3):6861. doi: 10.4081/rt.2017.6861. eCollection 2017 Oct 3.

5.

Store-operated calcium entry suppressed the TGF-β1/Smad3 signaling pathway in glomerular mesangial cells.

Chaudhari S, Li W, Wang Y, Jiang H, Ma Y, Davis ME, Zuckerman JE, Ma R.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F729-F739. doi: 10.1152/ajprenal.00483.2016. Epub 2017 Jun 21.

6.

Negative regulation of Smad1 pathway and collagen IV expression by store-operated Ca2+ entry in glomerular mesangial cells.

Wu P, Ren Y, Ma Y, Wang Y, Jiang H, Chaudhari S, Davis ME, Zuckerman JE, Ma R.

Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F1090-F1100. doi: 10.1152/ajprenal.00642.2016. Epub 2017 Mar 15.

7.

Small Cell Lung Cancer Presenting as a Cardiac Mass with Embolic Phenomena.

Duncan MD, Swinburne AJ, Sahni S, Zuckerman JE, Hacobian M.

Am J Med. 2017 Feb;130(2):e55-e57. doi: 10.1016/j.amjmed.2016.08.028. Epub 2016 Sep 13. No abstract available.

PMID:
27637599
8.

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.

Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3850-4. doi: 10.1073/pnas.1603018113. Epub 2016 Mar 21.

9.

Clinical experiences with systemically administered siRNA-based therapeutics in cancer.

Zuckerman JE, Davis ME.

Nat Rev Drug Discov. 2015 Dec;14(12):843-56. doi: 10.1038/nrd4685. Epub 2015 Nov 16. Review.

PMID:
26567702
10.

The human sex ratio from conception to birth.

Orzack SH, Stubblefield JW, Akmaev VR, Colls P, Munné S, Scholl T, Steinsaltz D, Zuckerman JE.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E2102-11. doi: 10.1073/pnas.1416546112. Epub 2015 Mar 30.

11.

Store-Operated Ca2+ Channels in Mesangial Cells Inhibit Matrix Protein Expression.

Wu P, Wang Y, Davis ME, Zuckerman JE, Chaudhari S, Begg M, Ma R.

J Am Soc Nephrol. 2015 Nov;26(11):2691-702. doi: 10.1681/ASN.2014090853. Epub 2015 Mar 18.

12.

siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.

Zuckerman JE, Gale A, Wu P, Ma R, Davis ME.

Nucleic Acid Ther. 2015 Apr;25(2):53-64. doi: 10.1089/nat.2014.0505. Epub 2015 Mar 3.

13.

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11449-54. doi: 10.1073/pnas.1411393111. Epub 2014 Jul 21.

14.

Targeting therapeutics to the glomerulus with nanoparticles.

Zuckerman JE, Davis ME.

Adv Chronic Kidney Dis. 2013 Nov;20(6):500-7. doi: 10.1053/j.ackd.2013.06.003. Review.

PMID:
24206602
15.

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.

Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, Schluep T, Chao J, Lin J, Yen Y, Han H, Wiley DT, Zuckerman JE, Davis ME.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15127-32. doi: 10.1073/pnas.1309566110. Epub 2013 Aug 26.

16.

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM.

J Control Release. 2012 May 10;159(3):384-92. doi: 10.1016/j.jconrel.2012.01.045. Epub 2012 Feb 8.

17.

Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

Zuckerman JE, Choi CH, Han H, Davis ME.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3137-42. doi: 10.1073/pnas.1200718109. Epub 2012 Feb 6.

18.

Targeting kidney mesangium by nanoparticles of defined size.

Choi CH, Zuckerman JE, Webster P, Davis ME.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61. doi: 10.1073/pnas.1103573108. Epub 2011 Apr 4.

19.

The C. elegans B-cell lymphoma 2 (Bcl-2) homolog cell death abnormal 9 (CED-9) associates with and remodels LIPID membranes.

Tan FJ, Zuckerman JE, Wells RC, Hill RB.

Protein Sci. 2011 Jan;20(1):62-74. doi: 10.1002/pro.536.

20.

siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.

Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A.

J Invest Dermatol. 2011 Feb;131(2):453-60. doi: 10.1038/jid.2010.310. Epub 2010 Oct 14.

21.

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A.

J Transl Med. 2010 Apr 20;8:39. doi: 10.1186/1479-5876-8-39.

22.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

23.

Anti-apoptotic Bcl-2 Family Proteins Disassemble Ceramide Channels.

Siskind LJ, Feinstein L, Yu T, Davis JS, Jones D, Choi J, Zuckerman JE, Tan W, Hill RB, Hardwick JM, Colombini M.

J Biol Chem. 2008 Mar 14;283(11):6622-30. doi: 10.1074/jbc.M706115200. Epub 2008 Jan 2.

24.

Labour pain management in a parturient with an implanted intrathecal pump.

Tarshis J, Zuckerman JE, Katz NP, Segal S, Mushlin PS.

Can J Anaesth. 1997 Dec;44(12):1278-81.

PMID:
9429046
25.

Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).

Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR Jr.

J Pharmacol Exp Ther. 1997 Sep;282(3):1173-80.

PMID:
9316823
26.

Toxicological properties of several novel oligonucleotide analogs in mice.

Henry SP, Zuckerman JE, Rojko J, Hall WC, Harman RJ, Kitchen D, Crooke ST.

Anticancer Drug Des. 1997 Jan;12(1):1-14.

PMID:
9051110
27.

Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH.

J Pharmacol Exp Ther. 1996 May;277(2):923-37.

PMID:
8627575
28.

A gelonin-containing immunotoxin directed against human breast carcinoma.

Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR.

Mol Biother. 1992 Sep;4(3):122-9.

PMID:
1445665
29.

Doxorubicin analogues incorporating chemically reactive substituents.

Farquhar D, Newman RA, Zuckerman JE, Andersson BS.

J Med Chem. 1991 Feb;34(2):561-4.

PMID:
1995877
30.

In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.

Zuckerman JE, Raffin TA, Brown JM, Newman RA, Etiz BB, Sikic BI.

Cancer Res. 1986 Apr;46(4 Pt 1):1748-53.

31.

Sodium n-butyrate enhancement of prostaglandin D2 antitumor efficacy.

Newman RA, Bauer DM, Zuckerman JE.

Biochem Pharmacol. 1985 Oct 15;34(20):3771-4. No abstract available.

PMID:
4052117
32.

Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro.

Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic BI, Raffin TA.

J Clin Invest. 1985 Jan;75(1):306-9.

33.

Effect of endotoxin on thiourea induced pulmonary edema and pleural effusion.

Hollinger MA, Patwell SW, Zuckerman JE.

Res Commun Chem Pathol Pharmacol. 1981 Feb;31(2):217-22.

PMID:
6784199
34.

Biochemical and structural alterations of hamster lungs in response to intratracheal administration of bleomycin.

Giri SN, Schwartz LW, Hollinger MA, Freywald ME, Schiedt MJ, Zuckerman JE.

Exp Mol Pathol. 1980 Aug;33(1):1-14. No abstract available.

PMID:
6157561
35.

Evaluation of antifibrotic drugs in bleomycin-induced pulmonary fibrosis in hamsters.

Zuckerman JE, Hollinger MA, Giri SN.

J Pharmacol Exp Ther. 1980 Jun;213(3):425-31.

PMID:
6162945
36.

Effect of paraquat on serum angiotensin converting enzyme.

Hollinger MA, Patwell SW, Zuckerman JE, Gorin AB, Parsons G, Giri SN.

Am Rev Respir Dis. 1980 May;121(5):795-8.

PMID:
6250433
37.

Effect of acute lung injury on angiotensin converting enzyme in serum, lung lavage, and effusate.

Hollinger MA, Giri SN, Patwell S, Zuckerman JE, Gorin A, Parsons G.

Am Rev Respir Dis. 1980 Feb;121(2):373-6.

PMID:
6244767
38.

E. coli septicemia in pregnancy associated with the shield intrauterine contraceptive device.

Zuckerman JE, Stubblefield PG.

Am J Obstet Gynecol. 1974 Dec 1;120(7):951-3. No abstract available.

PMID:
4611218
39.

Thyrotropin-releasing hormone is not the sole physiologic mediator of prolactin release during suckling.

Gautvik KM, Tashjian AH Jr, Kourides IA, Weintraub BD, Graeber CT, Maloof F, Suzuki K, Zuckerman JE.

N Engl J Med. 1974 May 23;290(21):1162-5. No abstract available.

PMID:
4207375
40.

Letter: Prenatal diagnosis.

Zuckerman JE.

Lancet. 1974 Feb 16;1(7851):261. No abstract available.

PMID:
4130261
41.

Serum prolactin and TSH: effects of nursing and pyroGlu-His-ProNH2 administration in postpartum women.

Gautvik KM, Weintraub BD, Graeber CT, Maloof F, Zuckerman JE, Tashjian AH Jr.

J Clin Endocrinol Metab. 1973 Jul;37(1):135-9. No abstract available.

PMID:
4715289
42.

In vitro localization of 67Ga in exfoliated epithelial cells from the uterine cervix.

Cobb CM, Zuckerman JE, Annis M.

Cancer Res. 1973 Jul;33(7):1578-84. No abstract available.

43.

Hemolytic disease of the newborn due to anti-Js a .

Donovan LM, Tripp KL, Zuckerman JE, Konugres AA.

Transfusion. 1973 May-Jun;13(3):153. No abstract available.

PMID:
4197052
44.

Cervical cord injuries secondary to hyperextension of the head in breech presentations.

Abroms IF, Bresnan MJ, Zuckerman JE, Fischer EG, Strand R.

Obstet Gynecol. 1973 Mar;41(3):369-78. No abstract available.

PMID:
4688255
45.

Human placental lactogen and the management of high-risk pregnancy.

Zuckerman JE.

Lancet. 1973 Jan 27;1(7796):200. No abstract available.

PMID:
4118810
46.

Effect of multiparity on human maternal hypersensitivity to foetal antigen.

Rocklin RE, Zuckerman JE, Alpert E, David JR.

Nature. 1973 Jan 12;241(5385):130-1. No abstract available.

PMID:
4695541
47.

Rapid, quantitative estimation of human placental lactogen in maternal serum by complement fixation.

Zuckerman JE, Fallon V, Tashjian AH Jr, Levine L, Friesen HG.

J Clin Endocrinol Metab. 1970 Jun;30(6):769-73. No abstract available.

PMID:
5444562
48.

Appearance of a brain specific antigen (th S-100 protein) during human foetal development.

Zuckerman JE, Herschman HR, Levine L.

J Neurochem. 1970 Feb;17(2):247-51. No abstract available.

PMID:
5531258

Supplemental Content

Loading ...
Support Center